ArticleBMC cancer2017
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Signal mining and analysis of influencing factors for adverse events of Nivolumab and Cetuximab in the treatment of head and neck cancer based on the US FAERS database.Frontiers in immunology · 2025Article
- Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon.Frontiers in immunology · 2023Article
- Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.Frontiers in medicine · 2023Article
- Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma.Molecular and clinical oncology · 2022Article
- Article
- Pseudoprogression in lung cancer: a case report.Exploration of targeted anti-tumor therapy · 2020Article
- The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.Cancer biology & medicine · 2019Article
- Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report.World journal of clinical oncology · 2019Article
- Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.Journal for immunotherapy of cancer · 2019Article
- A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.Clinical journal of gastroenterology · 2019Article
- Article
- How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.American journal of cancer research · 2019Review
- Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma.Thoracic cancer · 2018Article
- Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report.Thoracic cancer · 2018Article
- Gut microbiome modulates efficacy of immune checkpoint inhibitors.Journal of hematology & oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudoprogression refers to a specific pattern of response sometimes observed in malignant melanoma patients receiving treatment with immune-checkpoint inhibitors. Although cases with pseudoprogression documented once have been reported previously, there have been no case reports yet of pseudoprogression events documented twice during treatment. CASE PRESENTATION: A 55-year-old man underwent surgery for locally advanced esophageal malignant melanoma and received postoperative adjuvant interferon therapy. However, he presented with multiple liver and bone metastases at 6 months after the surgery, and was initiated on treatment with nivolumab 2 mg/kg every 3 weeks as the first-line treatment for recurrent disease. Follow-up computed tomography revealed that the liver metastases initially increased transiently in size, but eventually regressed. However, while the liver metastases continued to shrink, a new peritoneal nodule emerged, that also subsequently shrinked during the course of treatment with nivolumab. With only grade 1 pruritus, the patient continues to be on nivolumab treatment at 15 months after the induction therapy, with no progression observed after the second episode of pseudoprogression in the liver and peritoneal nodule.
conclusionsWe present the case of a patient with metastatic malignant melanoma who showed the unique response pattern of serial pseudoprogression during treatment with nivolumab. This case serves to highlight the fact that development of a new lesion may not always signify failure of disease control during treatment with nivolumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.